The Complete
GLP-1
Resource

Clinical data consistently shows that most patients regain a significant portion of lost weight after discontinuing GLP-1 therapy — on average, about two-thirds of lost weight returns within a year. This is because GLP-1 medications manage appetite neurologically; stopping them removes that suppression. This doesn't mean GLP-1s "don't work" — it means obesity is a chronic condition that often requires long-term management, similar to blood pressure medications. Some patients maintain results with lifestyle changes built during treatment. Read more on discontinuation →

There is no direct contraindication between GLP-1 medications and alcohol, but several important interactions exist. GLP-1s slow gastric emptying, which can alter how quickly alcohol is absorbed and intensify its effects at lower quantities. Many patients also report a spontaneous reduction in alcohol cravings — an area of active research. Heavy drinking significantly impairs weight loss results and increases pancreatitis risk, which is already a contraindication for these medications. Moderate alcohol consumption is generally considered acceptable; discuss your specific situation with your prescriber.

This is one of the most important concerns with rapid GLP-1-induced weight loss. Studies show that approximately 25–40% of total weight lost on semaglutide comes from lean mass (muscle), compared to the typical 20–25% from dietary restriction alone. This accelerated muscle loss is largely preventable with two strategies: adequate protein intake (1.2–1.6g per kg body weight daily) and progressive resistance training at least 2–3x per week. Some evidence suggests tirzepatide has a slightly more favorable lean mass preservation profile. Read our full muscle preservation guide →

The active ingredient — semaglutide or tirzepatide — is identical. The difference lies in regulatory approval and manufacturing oversight. Brand-name drugs (Ozempic, Wegovy, Mounjaro) are FDA-approved finished drug products with extensive clinical trial backing and standardized manufacturing. Compounded versions are produced in licensed compounding pharmacies (ideally 503B facilities) but are not individually FDA-approved. They are legal to prescribe when the active ingredient is on the FDA shortage list. Quality varies by pharmacy, making the pharmacy partner choice critical. Read our compounded vs. brand-name deep dive →

Coverage depends heavily on your insurer, employer plan, and specific diagnosis. Ozempic (approved for T2D) is covered by most commercial plans for diabetic patients. Wegovy (approved for obesity) has inconsistent coverage — many employers explicitly exclude it. Mounjaro/Zepbound follows a similar split. Medicare Part D does not currently cover GLP-1s for weight loss only, though legislation to change this has bipartisan support. Medicaid coverage varies by state. Compounded semaglutide from telehealth platforms is generally not covered. HSA/FSA accounts can be used for all prescribed GLP-1 costs. Read our insurance coverage guide →